← All trials
NCT05888922
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2024
- Primary completion
- Sep 30, 2024
- Completion date
- Feb 28, 2025
- First posted
- Jun 5, 2023
- Last posted
- Nov 28, 2023
- Enrollment
- 520
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Industrial Farmaceutica Cantabria, SpainLead sponsor
- Bioskin GmbHCollaborator
- Industrial Farmaceutica Cantabria, SpainStudy director
- BioClever 2005 S.L.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.